中智藥業(03737.HK)與美國生物醫藥公司GABAeron Inc.簽署投資協議
格隆匯12月23日丨中智藥業(03737.HK)公吿，2024年12月21日，集團與美國生物醫藥公司GABAeron Inc.投資協議簽約儀式在中山隆重舉行。GABAeron公司聯合創始人、董事長、着名神經科學家黃亞東博士，集團賴智填董事長，中山市健康基地集團有限公司萬鶴羣總經理、餘從洪副總經理等管理層出席活動並見證了簽約儀式，曹曉俊副總裁、喬衞林副總裁、賴穎盛首席財務官，王立峯律師一同出席活動。
根據投資協議，集團將以代價3,000,000美元認購GABAeron的3,000,000股A系列優先股，相當於GABAeron優先股的約11.5%持股權益。A系列優先股並不附有GABAeron的任何投票權。
GABAeron公司是一家位於美國舊金山，專注於體外誘導產生高純度中間神經元細胞，通過移植到大腦海馬區重建神經網絡，逆轉阿爾茨海默病(AD)進程，開發AD患者和其他神經系統疾病候選藥物的高科技創新公司。針對載脂蛋白E4(apoE4)是AD等多種神經退行性疾病的最強遺傳風險因素，GABAeron公司開發了一種新型療法，利用人類誘導型多能幹細胞(iPSC)的GABA能抑制中間神經元，治療攜帶apoE4基因（佔患者總數65%）的老年痴呆患者，以恢復損傷的海馬神經網絡。動物實驗已證實該方法能重建腦內認知整合中心海馬體和大腦相關皮層的正常神經活動，減緩或逆轉記憶和認知障礙。前期研究已通過FDAPre-IND審核，即將進入臨牀一期研究。未來有望為AD患者帶來新的臨牀治療方案。
集團秉承「智造健康生活」的核心價值觀，深耕中藥行業30餘年，致力於中藥飲片、中成藥和大健康產品的科研、生產和銷售，是現代創新飲片品類中藥破壁飲片的發明者和行業引領者。公司於2015年在香港聯交所上市，並已建立了國家企業技術中心、國家地方聯合工程研究中心等科研平台，通過持續的科技創新，為消費者提供安全高品質、應用便捷的中藥產品，助力中醫藥的傳承創新，推動產業發展。
集團此次投資GABAeron公司，將助力推進GABAeron的GR01細胞移植治療AD臨牀試驗的實施，為未來的Ⅱ、Ⅲ期臨牀試驗奠定堅實的基礎，最終實現產品上市，為全球廣大AD患者緩解和逆轉症狀，改善其生活質量，造福億萬患者及其家庭，標誌着集團在生物醫藥領域的戰略佈局邁向新台階！
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
